ELTX vs PATH · $132.3M cap vs P/E 19, rev $1.61B
Elicio Therapeutics Inc. (ELTX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Elicio Therapeutics Inc. (ELTX) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ELTX revenue for 2023-03-31 was $0. Net income was -$8.0M. Revenue was down 100.0% from 2022-12-31 to 2023-03-31. ELTX currently screens at market cap $132.3M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ELTX currently screens at market cap $132.3M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ELTX and PATH stock pages for the full models.
Not investment advice.